Clinical Trials on Prostatic Cancer

Total 53334 results

Assistance Publique - Hôpitaux de Paris

Suspended

Study to Evaluate the Clinical Impact of a Laparoscopic Radical Prostatectomy Simulator (PERLE)

Prostatic Neoplasms | Prostate Cancer | Prostate Neoplasms | Cancer of Prostate

France
University of Southern California
National Cancer Institute (NCI); Sanofi

Terminated

Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

Diarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Fundacao Champalimaud

Unknown

Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer

Metastatic Prostate Cancer | Prostate Adenocarcinoma

Portugal
National Cancer Institute (NCI)

Completed

Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Tivantinib in Treating Patients With Metastatic Prostate Cancer

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
AstraZeneca

Completed

Retrospective Study to Describe the Real-world Treatment Patterns and Associated Clinical Outcomes in Patients With Metastatic Castration-resistant Prostates Cancer (REMPRO)

Metastatic Castration-resistant Prostates Cancer

India, Peru, Saudi Arabia, Egypt, Colombia, Korea, Republic of, Turkey, United Arab Emirates
NanOlogy, LLC
US Biotest, Inc.

Terminated

Trial of NanoPac Focal Therapy for Prostate Cancer

Urogenital Neoplasms | Genital Neoplasms, Male | Prostate Cancer | Prostate Adenocarcinoma | Prostatic Neoplasm | Localized Cancer | Prostate Cancer Adenocarcinoma

United States
Jeanne Link
Oregon Health and Science University; OHSU Knight Cancer Institute; OHSU Center...

Approved for marketing

Expanded Access Protocol of 68Ga PSMA 11 PET Imaging of Prostate Cancer

Prostatic Neoplasms | Prostatic Diseases | Prostate Cancer | Prostate Cancer Recurrent | Prostate Cancer Metastatic

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients

Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Hormone-Resistant Prostate Cancer

United States
Jonsson Comprehensive Cancer Center

Completed

68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery

Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v7 | Stage III Prostate Cancer AJCC v7 | Stage IIB Prostate Cancer AJCC v7

United States
Janux Therapeutics

Recruiting

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

Prostate Cancer | Metastatic Castration-resistant Prostate Cancer | Castration Resistant Prostatic Cancer

United States, Australia
National Cancer Institute (NCI)

Completed

BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Recurrent Prostate Cancer | Bone Metastases | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer

Recurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Community Cancer Center, Normal, Illinois

Unknown

A Phase II Trial of CyberKnife Stereotactic Radiosurgery to Prostate Tumors

Prostate Cancer | Prostate Neoplasm | Cancer of the Prostate

United States
Hospital Universitari Vall d'Hebron Research Institute

Unknown

Comparison of Prostate Fusion Biopsies With Software and Cognitive

Prostate Cancer Detection | Fusion Prostate Biopsy

Spain
Northwestern University
Genzyme, a Sanofi Company

Withdrawn

Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer

PROSTATE CANCER

United States
Progenics Pharmaceuticals, Inc.

Active, not recruiting

Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone (ARROW)

Castration-resistant Prostate Cancer | Metastatic Prostate Cancer | Cancer of the Prostate | Prostatic Neoplasm | Progressive mCRPC

United States, Canada
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
AstraZeneca

Recruiting

The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation (PROspect)

Prostate Cancer | Prostate Carcinoma | Metastatic Castration-resistant Prostate Cancer

China
National Cancer Institute (NCI)

Completed

17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Ixabepilone in Treating Patients With Metastatic Prostate Cancer

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Massachusetts General Hospital
Bayer

Completed

A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer

Prostate Cancer | Castration-resistant Prostate Cancer | Castration-resistant Prostate Cancer Metastatic to Bone

United States
National Cancer Institute (NCI)

Completed

AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer

United States
University of Washington
National Cancer Institute (NCI); AstraZeneca

Terminated

Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer

Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Prostate Adenocarcinoma Without Neuroendocrine Differentiation

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer

Recurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
The University of Texas Health Science Center at...

Withdrawn

Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients (HIIT PCa)

Metastatic Prostate Cancer | Prostate Cancer Metastatic | Metastatic Prostate Adenocarcinoma | Castrate Resistant Prostate Cancer

United States
Centocor, Inc.

Terminated

A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)

Cancer, Prostate

United States, United Kingdom, Belgium, Germany, Spain, France, Austria
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients

Hormone Refractory Prostate Cancer | Metastatic Prostate Carcinoma

China
Astellas Pharma Inc
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients

Prostate Cancer | Prostate Neoplasms | Castration Resistant Prostate Cancer (CRPC)

Japan
University of Southern California
National Cancer Institute (NCI)

Terminated

Molecular Characterization of CTCs and ctDNA in Blood and Plasma Samples From Patients With Metastatic and/or Hormone-Resistant Prostate Cancer

Metastatic Prostate Carcinoma | Hormone-Resistant Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Northwestern University

Recruiting

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Refractory Prostate Cancer | Castration-Resistant Prostatic Cancer

United States
Centre Hospitalier Universitaire de Saint Etienne
National Cancer Institute, France

Completed

Physical Activity Experiment on Male Prostate Cancer Patients (ACTI_PAIR)

Cancer Prostate

France
Fundacao Champalimaud

Completed

Phase II Study of Ultra-high-dose Hypofractionated vs. Single-dose Image-Guided Radiotherapy for Prostate Cancer (PROSINT)

PROSTATE CANCER

Portugal
University College London Hospitals

Completed

Prostate Cancer Genomic Heterogeneity (PROGENY)

PROSTATE CANCER

United Kingdom
GenSpera, Inc.

Withdrawn

Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer

Prostate Cancer.

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel

Recurrent Prostate Cancer | Hormone Refractory Prostate Cancer

United States, Canada
National Cancer Institute (NCI)

Completed

Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer

Recurrent Prostate Cancer | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Cilengitide in Treating Patients With Metastatic Prostate Cancer

Recurrent Prostate Cancer | Stage IV Prostate Cancer

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Recruiting

Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer

Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8

United States
Jonsson Comprehensive Cancer Center

Withdrawn

Focal Radiation Therapy for the Treatment of Low or Intermediate-Risk Prostate Cancer

Prostate Adenocarcinoma | Stage II Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8

United States
Weill Medical College of Cornell University
Millennium Pharmaceuticals, Inc.

Completed

A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer

Neuroendocrine Prostate Cancer | Small Cell Prostate Cancer | Prostate Adenocarcinoma Plus > 50% Immunohistochemical Staining for Neuroendocrine Markers

United States
Stanford University
National Cancer Institute (NCI)

Active, not recruiting

High-Dose Brachytherapy in Treating Patients With Prostate Cancer

Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
National Cancer Institute (NCI)

Terminated

Photodynamic Therapy With Lutetium Texaphyrin in Treating Patients With Locally Recurrent Prostate Cancer

Recurrent Prostate Cancer | Stage I Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
MacroGenics

Recruiting

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer Recurrent | Immunotherapy | Androgen-Independent Prostatic Cancer | Androgen-Resistant Prostatic Cancer | Hormone Refractory Prostatic Cancer | Immune Checkpoint Inhibitor | Androgen-Independent Prostatic Neoplasms | Androgen-Insensitive Prostatic Cance | Inhibitory Checkpoint Molecule

United States, Spain, France, Belgium, United Kingdom, Poland, Georgia, Bulgaria, Puerto Rico, Australia
University of Chicago
National Cancer Institute (NCI)

Completed

MR-Guided Laser Interstitial Thermal Therapy in Treating Patients With Prostate Cancer

Stage II Prostate Carcinoma | Stage I Prostate Cancer

United States
Peter Busch Østergren

Recruiting

National Danish Protocol. Surgery+ SBRT for M1 Prostate Cancer Patients (Oligomet_DK)

Prostate Cancer Metastatic

Denmark

Clinical Trials on Prostatic Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations